In vivo pharmacokinetic study of antibody conjugates

The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is issuing a non-competitive Firm-Fixed-Price Purchase Order under FAR 6.302-1 for an in vivo pharmacokinetic study of antibody-lectin conjugates, sole-sourced to The Jackson Laboratory due to unusual and compelling urgency and the organization’s unique scientific capabilities. The work involves administering conjugates intravenously to transgenic B6.Cg-Fcgrttm1Dcr Prkdscid Tg(FCGRT)32Dcr/DcrJ mice expressing the human FcRn receptor and measuring serum concentrations over time using ELISA to determine serum half-life, supporting preclinical development of antiviral therapies. The performance location is Bethesda, Maryland, and responses must be submitted as a capability statement via email to [email hidden] by 11:00 p.m. EDT on June 12, 2026. No competitive evaluation factors, pricing details, or contract value are disclosed, as this is a notice of intent and not a full solicitation. No contract clauses, packaging requirements, inspection criteria, or formal delivery schedules are specified, and no detailed accounting, payment, or invoicing information is provided. While the document references eligibility for small business categories, no certifications or representations from the awardee are included or confirmed, and no official contracting officer, COR, or COTR is named. The procurement is justified solely on the basis of prior relationship and urgent research continuity needs.